Perioperative Pain Management and Cancer Outcomes: A Narrative Review

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Nestvold K, Lundar T, Blikra G, et al. Head injuries during one year in a central hospital in Norway: a prospective study. Epidemiologic features. Neuroepidemiology. 1988;7(3):134–144. doi:10.1159/000110147
   PubMed Web of Science ®Google Scholar
• Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care. 2002;6(4):298–305. doi:10.1186/cc1514
   PubMed Web of Science ®Google Scholar
• Cole SW, Nagaraja AS, Lutgendorf SK, et al. Sympathetic nervous system regulation of the tumour microenvironment. Nat Rev Cancer. 2015;15(9):563–572. doi:10.1038/nrc3978
   PubMed Web of Science ®Google Scholar
• Benzonana LL, Perry NJS, Watts HR, et al. Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant potential via the hypoxia-inducible factor cellular signaling pathway in vitro. Anesthesiology. 2013;119(3):593–605. doi:10.1097/ALN.0b013e31829e47fd
   PubMed Web of Science ®Google Scholar
• Cata JP, Corrales G, Speer B, et al. Postoperative acute pain challenges in patients with cancer. Best Pract Res Clin Anaesthesiol. 2019;33(3):361–371. doi:10.1016/j.bpa.2019.07.018
   PubMed Web of Science ®Google Scholar
• McGreevy K, Bottros MM, Raja SN. Preventing chronic pain following acute pain: risk factors, preventive strategies, and their efficacy. Eur J Pain Suppl. 2011;5(2):365–372. doi:10.1016/j.eujps.2011.08.013
   PubMedGoogle Scholar
• Hill BL, Lefkowits C. Strategies for optimizing perioperative pain management for the cancer patient. Surg Oncol Clin N Am. 2021;30(3):519–534. doi:10.1016/j.soc.2021.02.011
   PubMed Web of Science ®Google Scholar
• Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022;22(5):190–196. doi:10.1016/j.bjae.2021.11.008
   PubMed Web of Science ®Google Scholar
• O’Neill A, Lirk P. Multimodal analgesia. Anesthesiol Clin. 2022;40(3):455–468. doi:10.1016/j.anclin.2022.04.002
   PubMedGoogle Scholar
• Helander EM, Menard BL, Harmon CM, et al. Multimodal analgesia, current concepts, and acute pain considerations. Curr Pain Headache Rep. 2017;21(1):3. doi:10.1007/s11916-017-0607-y
   PubMed Web of Science ®Google Scholar
• Tegeder I, Grösch S, Schmidtko A, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63(8):1846–1852.
   PubMed Web of Science ®Google Scholar
• Yeager MP, Colacchio TA. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg. 1991;126(4):454–456. doi:10.1001/archsurg.1991.01410280056007
   PubMedGoogle Scholar
• Gach K, Wyrębska A, Fichna J, et al. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(3):221–230. doi:10.1007/s00210-011-0672-4
   PubMed Web of Science ®Google Scholar
• Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011;6(4):442–465. doi:10.1007/s11481-011-9292-5
   PubMed Web of Science ®Google Scholar
• Alam A, Rampes S, Patel S, et al. Anesthetics or anesthetic techniques and cancer surgical outcomes: a possible link. Korean J Anesthesiol. 2021;74(3):191–203. doi:10.4097/kja.20679
   PubMed Web of Science ®Google Scholar
• Hernandez MC, Flores LR, Bayer BM. Immunosuppression by morphine is mediated by central pathways. J Pharmacol Exp Ther. 1993;267(3):1336–1341.
   PubMed Web of Science ®Google Scholar
• Yu Z, Jin S, Tian S, et al. Morphine stimulates cervical cancer cells and alleviates cytotoxicity of chemotherapeutic drugs via opioid receptor-dependent and -independent mechanisms. Pharmacol Res Perspect. 2022;10(5):e01016. doi:10.1002/prp2.1016
   PubMed Web of Science ®Google Scholar
• Feng T, Zeng S, Ding J, et al. Comparative analysis of the effects of opioids in angiogenesis. BMC Anesthesiol. 2021;21(1):257. doi:10.1186/s12871-021-01475-7
   PubMed Web of Science ®Google Scholar
• Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014;3(4):900–908. doi:10.1002/cam4.236
   PubMed Web of Science ®Google Scholar
• Tai YH, Wu H-L, Chang W-K, et al. Intraoperative fentanyl consumption does not impact cancer recurrence or overall survival after curative colorectal cancer resection. Sci Rep. 2017;7(1):10816. doi:10.1038/s41598-017-11460-1
   PubMedGoogle Scholar
• Montagna G, Gupta HV, Hannum M, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth. 2021;126(2):367–376. doi:10.1016/j.bja.2020.10.021
   PubMed Web of Science ®Google Scholar
• Zheng J, He J, Wang W, et al. The impact of pain and opioids use on survival in cancer patients: results from a population-based cohort study and a meta-analysis. Medicine. 2020;99(9):e19306. doi:10.1097/MD.0000000000019306
   PubMed Web of Science ®Google Scholar
• Lee S. Dexmedetomidine: present and future directions. Korean J Anesthesiol. 2019;72(4):323–330. doi:10.4097/kja.19259
   PubMed Web of Science ®Google Scholar
• Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913. doi:10.1007/s40262-017-0507-7
   PubMed Web of Science ®Google Scholar
• Dong W, Chen M-H, Yang Y-H, et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21(15):3510–3515.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Huang CY, Hua YP, et al. Dexmedetomidine reduces intestinal and hepatic injury after hepatectomy with inflow occlusion under general anaesthesia: a randomized controlled trial. Br J Anaesth. 2014;112(6):1055–1064. doi:10.1093/bja/aeu132
   PubMed Web of Science ®Google Scholar
• Wang K, Li C. Effects of dexmedetomidine on inflammatory factors, T lymphocyte subsets and expression of NF-kappaB in peripheral blood mononuclear cells in patients receiving radical surgery of colon carcinoma. Oncol Lett. 2018;15(5):7153–7157. doi:10.3892/ol.2018.8205
   PubMed Web of Science ®Google Scholar
• Cata JP, Singh V, Lee B, et al. Intraoperative use of dexmedetomidine is associated with decreased overall survival after lung cancer surgery. J Anaesthesiol Clin Pharmacol. 2017;33(3):317–323. doi:10.4103/joacp.JOACP_299_16
   PubMedGoogle Scholar
• Ren B, Cheng M, Liu C, et al. Perioperative lidocaine and dexmedetomidine intravenous infusion reduce the serum levels of NETs and biomarkers of tumor metastasis in lung cancer patients: a prospective, single-center, double-blinded, randomized clinical trial. Front Oncol. 2023;13:1101449. doi:10.3389/fonc.2023.1101449
   PubMed Web of Science ®Google Scholar
• Cho JS, Seon K, Kim M-Y, et al. Effects of perioperative dexmedetomidine on immunomodulation in uterine cancer surgery: a randomized, controlled trial. Front Oncol. 2021;11:749003. doi:10.3389/fonc.2021.749003
   PubMed Web of Science ®Google Scholar
• Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth. 1981;53(1):27–30. doi:10.1093/bja/53.1.27
   PubMed Web of Science ®Google Scholar
• Loftus RW, Yeager MP, Clark JA, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology. 2010;113(3):639–646. doi:10.1097/ALN.0b013e3181e90914
   PubMed Web of Science ®Google Scholar
• Loveday BA, Sindt J. Ketamine protocol for palliative care in cancer patients with refractory pain. J Adv Pract Oncol. 2015;6(6):555–561.
   PubMedGoogle Scholar
• Orhurhu V, Orhurhu MS, Bhatia A, et al. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. 2019;129(1):241–254. doi:10.1213/ANE.0000000000004185
   PubMed Web of Science ®Google Scholar
• Kapural L, Kapural M, Bensitel T, Sessler DI. Opioid-sparing effect of intravenous outpatient ketamine infusions appears short-lived in chronic-pain patients with high opioid requirements. Pain Physician. 2010;13(4):389–394. doi:10.36076/ppj.2010/13/389
   PubMed Web of Science ®Google Scholar
• Duan W, Hu J, Liu Y. Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor. Exp Mol Pathol. 2019;107:171–178. doi:10.1016/j.yexmp.2019.02.004
   PubMed Web of Science ®Google Scholar
• Li H, Liu W, Zhang X, et al. Ketamine suppresses proliferation and induces ferroptosis and apoptosis of breast cancer cells by targeting KAT5/GPX4 axis. Biochem Biophys Res Commun. 2021;585:111–116. doi:10.1016/j.bbrc.2021.11.029
   PubMed Web of Science ®Google Scholar
• Malsy M, Gebhardt K, Gruber M, et al. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol. 2015;15(1):111. doi:10.1186/s12871-015-0076-y
   PubMedGoogle Scholar
• Li T, Yang J, Yang B, et al. Ketamine inhibits ovarian cancer cell growth by regulating the lncRNA-PVT1/EZH2/p57 axis. Front Genet. 2020;11:597467. doi:10.3389/fgene.2020.597467
   PubMed Web of Science ®Google Scholar
• Connolly JG, Tan KS, Mastrogiacomo B, et al. Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. Br J Anaesth. 2021;127(1):75–84. doi:10.1016/j.bja.2021.03.030
   PubMed Web of Science ®Google Scholar
• Cho JS, Young KN, Jae-Kwang S, et al. The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. Can J Anaesth. 2021;68(5):683–692. doi:10.1007/s12630-021-01925-3
   PubMed Web of Science ®Google Scholar
• Silagy AW, Hannum ML, Mano R, et al. Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. Br J Anaesth. 2020;125(5):e402–e404. doi:10.1016/j.bja.2020.06.036
   PubMed Web of Science ®Google Scholar
• Forget P, Machiels J-P, Coulie PG, et al. Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol. 2013;20(Suppl 3):S650–S660. doi:10.1245/s10434-013-3136-x
   PubMed Web of Science ®Google Scholar
• Masic D, Liang E, Long C, et al. Intravenous lidocaine for acute pain: a systematic review. Pharmacotherapy. 2018;38(12):1250–1259. doi:10.1002/phar.2189
   PubMed Web of Science ®Google Scholar
• Chu R, Umukoro N, Greer T, et al. Intravenous lidocaine infusion for the management of early postoperative pain: a comprehensive review of controlled trials. Psychopharmacol Bull. 2020;50(4 Suppl 1):216–259.
   PubMedGoogle Scholar
• Zhang C, Xie C, Lu Y. Local anesthetic lidocaine and cancer: insight into tumor progression and recurrence. Front Oncol. 2021;11:669746. doi:10.3389/fonc.2021.669746
   PubMed Web of Science ®Google Scholar
• Ramirez MF, Tran P, Cata JP. The effect of clinically therapeutic plasma concentrations of lidocaine on natural killer cell cytotoxicity. Reg Anesth Pain Med. 2015;40(1):43–48. doi:10.1097/AAP.0000000000000191
   PubMed Web of Science ®Google Scholar
• Zhang H, Qu M, Guo K, et al. Intraoperative lidocaine infusion in patients undergoing pancreatectomy for pancreatic cancer: a mechanistic, multicentre randomised clinical trial. Br J Anaesth. 2022;129(2):244–253. doi:10.1016/j.bja.2022.03.031
   PubMed Web of Science ®Google Scholar
• Zhang H, Gu J, Qu M, et al. Effects of intravenous infusion of lidocaine on short-term outcomes and survival in patients undergoing surgery for ovarian cancer: a retrospective propensity score matching study. Front Oncol. 2021;11:689832. doi:10.3389/fonc.2021.689832
   PubMed Web of Science ®Google Scholar
• Wei Q, Xia M, Zhang Q, et al. Effect of intravenous lidocaine infusion on perioperative cellular immunity and the quality of postoperative recovery in breast cancer patients: a randomized controlled trial. Gland Surg. 2022;11(3):599–610. doi:10.21037/gs-22-134
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang L, Zhu X, et al. Association between intraoperative intravenous lidocaine infusion and survival in patients undergoing pancreatectomy for pancreatic cancer: a retrospective study. Br J Anaesth. 2020;125(2):141–148.
   PubMed Web of Science ®Google Scholar
• Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 2003;63(18):6096–6101.
   PubMed Web of Science ®Google Scholar
• Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21(4):756–762. doi:10.1158/1078-0432.CCR-14-2235
   PubMed Web of Science ®Google Scholar
• Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106(7):1340–1350. doi:10.1038/ajg.2011.38
   PubMed Web of Science ®Google Scholar
• Kolawole OR, Kashfi K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int J Mol Sci. 2022;23(3):1432. doi:10.3390/ijms23031432
   PubMed Web of Science ®Google Scholar
• Schack A, Fransgaard T, Klein MF, et al. Perioperative use of nonsteroidal anti-inflammatory drugs decreases the risk of recurrence of cancer after colorectal resection: a cohort study based on prospective data. Ann Surg Oncol. 2019;26(12):3826–3837. doi:10.1245/s10434-019-07600-8
   PubMed Web of Science ®Google Scholar
• Grahn O, Lundin M, Lydrup M-L, et al. Postoperative non-steroidal anti-inflammatory drug use and oncological outcomes of rectal cancer. BJS Open. 2021;5(1). doi:10.1093/bjsopen/zraa050
   PubMed Web of Science ®Google Scholar
• Retsky M, Rogers R, Demicheli R, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881–888. doi:10.1007/s10549-012-2094-5
   PubMed Web of Science ®Google Scholar
• Desmedt C, Demicheli R, Fornili M, et al. Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the Patient’s Body Mass Index. J Natl Cancer Inst. 2018;110(10):1115–1122. doi:10.1093/jnci/djy042
   PubMedGoogle Scholar
• Forget P, Bentin C, Machiels J-P, et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113(Suppl 1):i82–i87. doi:10.1093/bja/aet464
   PubMedGoogle Scholar
• de Castro Araujo BL, de Oliveira JL, Rezende JFN, et al. Impact of non-steroidal anti-inflammatory drugs on recurrence and survival after melanoma surgery: a cohort study. Cancer Invest. 2020;38(7):415–423. doi:10.1080/07357907.2020.1793351
   PubMed Web of Science ®Google Scholar
• Connolly JG, Scarpa JR, Gupta HV, et al. Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis. Br J Anaesth. 2021;127(3):e82–e85. doi:10.1016/j.bja.2021.05.032
   PubMed Web of Science ®Google Scholar
• Mao S, Wu Y, Wang R, et al. Intraoperative use of single dose of nonsteroidal anti-inflammatory drugs was not associated with cancer recurrence and mortality after bladder cancer surgery: a retrospective study. Ann Palliat Med. 2020;9(1):8–18. doi:10.21037/apm.2019.11.27
   PubMed Web of Science ®Google Scholar
• Wuethrich PY, Hsu Schmitz S-F, Kessler TM, et al. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. Anesthesiology. 2010;113(3):570–576. doi:10.1097/ALN.0b013e3181e4f6ec
   PubMed Web of Science ®Google Scholar
• Forget P, Tombal B, Scholtès J-L, et al. Do intraoperative analgesics influence oncological outcomes after radical prostatectomy for prostate cancer? Eur J Anaesthesiol. 2011;28(12):830–835. doi:10.1097/EJA.0b013e32834b7d9a
   PubMed Web of Science ®Google Scholar
• Shaji S, Smith C, Forget P. Perioperative NSAIDs and long-term outcomes after cancer surgery: a systematic review and meta-analysis. Curr Oncol Rep. 2021;23(12):146. doi:10.1007/s11912-021-01133-8
   PubMed Web of Science ®Google Scholar